Trial intelligence / Profile preview

Efficacy and Safety of UK-390,957 in Premature Ejaculation

NCT00219635Phase 3Completed

Sponsor
Pfizer
Start
Jan 2005
Primary completion
Jul 2005
Modality
Small Molecules
Countries
4
01

Overview

Phase 3, randomised, double-blind trial in premature ejaculation (PE) comparing UK-390,957 with Placebo (2 arms). Primary endpoint: Assessment of efficacy and safety. Started Jan 2005; status: completed.

02

Drugs

UK-390957
03

Conditions

premature ejaculation (PE)

Beyond the preview

Go deeper on NCT00219635.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT00219635.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call